欧美自拍另类欧美宗合图片区,国产视频一区二区三区四区,日本一区二区三区四区视频,婬片一区AAA毛片一区二区

商品編號


AG-20B-0023PF-C100



品牌


Adipogen



公司


Adipogen



公司分類(lèi)


Antibodies



Size

100 ?g


商品信息


More Information



Product Details



Synonyms

TRAIL Receptor 2; DR5; KILLER; TNFRSF10B; CD262



Product Type

Monoclonal Antibody



Properties



Clone

HS201



Isotype

Mouse IgG1



Source/Host

Purified from concentrated hybridoma tissue culture supernatant.



Immunogen/Antigen

Recombinant human TRAIL-R2 (DR5).



Application


Flow Cytometry

Functional Application:
Inhibition (blocks TRAIL-R2 mediated killing if applied in solution).

Immunocytochemistry

Immunoprecipitation




Crossreactivity

Human



Specificity

Recognizes human TRAIL-R2. Does not cross-react with human TRAIL-R1, -R3 or -R4.



Purity

≥95% (SDS-PAGE)



Purity Detail

Protein G-affinity purified.



Concentration

1mg/ml



Formulation

Liquid. In PBS containing 10% glycerol.



Shipping and Handling



Shipping

BLUE ICE



Short Term Storage

+4°C



Long Term Storage

-20°C



Handling Advice

After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.



Use/St
ABI
lity

Stable for at least 1 year after receipt when stored at -20°C.



Documents



MSD
S


Download PDF



Product Specification Sheet



Datasheet


Download PDF





TRAIL-R2 is a receptor for the cytotoxic ligand TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-κB.


Product References

Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8: M.R. Sprick, et al.; EMBO J.
21,
4520 (2002)

Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Signaling in Activated T Cells Abrogates TRAIL-Induced Apoptosis Upstream of the Mitochondrial Amplification Loop and Caspase-8: T.S. Soderstrom, et al.; J. Immunol.
169,
2851 (2002)

Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis: H. Higuchi, et al.; J. Biol. Chem.
278,
454 (2003)

Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation: M. Leverkus, et al.; Mol. Cell. Biol.
23,
777 (2003)

TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus: B. Washburn, et al.; J. Immunol.
170,
1814 (2003)

Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs: T.M. Ganten, et al.; Cell Death Differ.
11 Suppl 1,
86 (2004)

Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex: K. Izeradjene, et al.; Cancer Res.
64,
8036 (2004)

Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5: T.G. Jin, et al.; J. Biol. Chem.
279,
55594 (2004)

TRAIL regulates normal erythroid maturation through an ERK-dependent pathway: P. Secchiero, et al.; Blood
103,
517 (2004)

IFN{alpha}-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells: C. Tecchio, et al.; Blood
103,
3837 (2004)

cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes: T. Wachter, et al.; J. Biol. Chem.
279,
52824 (2004)

Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression: E. Contassot, et al.; Blood
111,
4780 (2008)

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells: M.H. Tuthill, et al.; Oncogene
34,
2138 (2015)